The European Patent Office (EPO) has published patent application EP4709418A1, filed on March 18, 2026, by Sanofi Pasteur Inc. and the U.S. Department of Health and Human Services. The application pertains to a Respiratory Syncytial Virus (RSV) vaccine and methods of its use. This publication represents the formal disclosure of intellectual property related to a potential new vaccine.

This is a patent application filing, not a regulatory approval or a rule that imposes new compliance obligations on drug manufacturers. Compliance officers should note this filing as it pertains to intellectual property within the pharmaceutical sector, particularly concerning vaccine development. No immediate actions are required based on this patent publication.